David Moriarty, Ph.D.

SVP, Clinical Operations

David Moriarty, Ph.D., has nearly 25 years of clinical research experience. Previously, Dr. Moriarty led Clinical Operations for an autoimmune-focused cell therapy company, bringing forward CAR-T cell trials across autoimmune indications in rheumatology and neurology. Before that, he led Clinical Operations and Compliance for Horizon Therapeutics globally prior to Horizons’ acquisition by Amgen, focused on autoimmune and rare disease development. Preceding Horizon, Dr. Moriarty was at Zogenix working on rare epilepsy development work prior to their acquisition by UCB. From 2018 to 2021, he built Development Operations at Spruce through their Series A and B financings and subsequent IPO growth phase in rare endocrine disorders. From 2015 to 2018, Dr. Moriarty was at Jazz Pharmaceuticals with responsibility for Clinical Operations and Data Management. Preceding this time, he spent 10 years at Janssen Pharmaceuticals in positions of increasing responsibility across HIV medicine and subsequently the late-stage Alzheimer’s clinical trial work. Dr. Moriarty entered the industry via PPD and when working for the CRO in positions of increasing responsibility worked on trials that were part of the development of Humira for autoimmune indications. Dr. Moriarty received his Ph.D. in neuroscience from the University of Manchester, UK.